Subgroups according to BASDAI/ASDAS category (baseline)

Por um escritor misterioso

Descrição

Subgroups according to BASDAI/ASDAS category (baseline)
A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis, Arthritis Research & Therapy
Subgroups according to BASDAI/ASDAS category (baseline)
Disease activity status at baseline stratified by BASDAI and ASDAS.
Subgroups according to BASDAI/ASDAS category (baseline)
Measuring quality of life of patients with axial spondyloarthritis for economic evaluation
Subgroups according to BASDAI/ASDAS category (baseline)
Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort
Subgroups according to BASDAI/ASDAS category (baseline)
WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents
Subgroups according to BASDAI/ASDAS category (baseline)
Extended Report Semantic Scholar
Subgroups according to BASDAI/ASDAS category (baseline)
Full article: POSTER PRESENTATIONS
Subgroups according to BASDAI/ASDAS category (baseline)
Extended Report Semantic Scholar
Subgroups according to BASDAI/ASDAS category (baseline)
JCM, Free Full-Text
Subgroups according to BASDAI/ASDAS category (baseline)
Mean ASDAS and other clinical parameters in disease activity subgroups
Subgroups according to BASDAI/ASDAS category (baseline)
A) Ankylosing Spondylitis Disease Activity Score (ASDAS) clinically
Subgroups according to BASDAI/ASDAS category (baseline)
IJMS, Free Full-Text
Subgroups according to BASDAI/ASDAS category (baseline)
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials
Subgroups according to BASDAI/ASDAS category (baseline)
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
Subgroups according to BASDAI/ASDAS category (baseline)
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
de por adulto (o preço varia de acordo com o tamanho do grupo)